Biochimica et biophysica acta. Reviews on cancer最新文献

Mechanism of interleukin-6 cytokine family in bone metastasis of lung cancer and prospects for its application 白细胞介素-6细胞因子家族在肺癌骨转移中的作用机制及应用前景。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-24 DOI: 10.1016/j.bbcan.2025.189398

Jinbai Huang , Qingting Zhang , Yuanshan Yang , Wei Wang , Jun Cai

{"title":"Mechanism of interleukin-6 cytokine family in bone metastasis of lung cancer and prospects for its application","authors":"Jinbai Huang , Qingting Zhang , Yuanshan Yang , Wei Wang , Jun Cai","doi":"10.1016/j.bbcan.2025.189398","DOIUrl":"10.1016/j.bbcan.2025.189398","url":null,"abstract":"<div><div>Bone metastasis is a significant clinical problem for lung cancer patients. Current studies have reported a strong relationship between the progression of bone metastases from lung cancer and inflammatory cytokines, which can modulate the tumor microenvironment (TME) and promote the migration of tumor cells. Interleukin-6 (IL-6) family cytokines are critical components of the immune microenvironment secreted by several cell types in vivo. They can regulate immune homeostasis, inflammatory response, etc., and activate multiple signal pathways involved in tumor progression. Some of these factors (e.g., IL-6 and IL-11) increase the serum expression levels of patients with bone metastases from lung cancer; the level of expression correlates with a poor prognosis in patients with lung cancer. However, the role of this family of novel cytokines in lung cancer bone metastasis remains unclear. Besides, limited studies exist on the related regulatory mechanisms, and there is a lack of direct evidence for their relationship with bone metastasis. Thus, this review discusses the current roles and potential mechanisms of all IL-6 family members in lung cancer bone metastasis, as well as the potential of blocking the IL-6 family, its receptors, and signaling pathways for treating lung cancer bone metastasis. This is geared towards providing prospective treatment targets for bone metastases from lung cancer and possible future research directions.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189398"},"PeriodicalIF":9.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research advances on amino acid starvation interventions for hepatocellular carcinoma 氨基酸饥饿干预肝癌的研究进展。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-24 DOI: 10.1016/j.bbcan.2025.189400

Yanqi Li , Lin Li , Yongyong Hou , Xueqiang Peng , Hangyu Li

{"title":"Research advances on amino acid starvation interventions for hepatocellular carcinoma","authors":"Yanqi Li , Lin Li , Yongyong Hou , Xueqiang Peng , Hangyu Li","doi":"10.1016/j.bbcan.2025.189400","DOIUrl":"10.1016/j.bbcan.2025.189400","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is an aggressive malignancy associated with high mortality. Numerous endeavors have been undertaken to develop more effective pharmaceutical interventions. Metabolic reprogramming is recognized as a hallmark of cancer for adapting to heightened bioenergetic and biosynthetic demands. Amino acid (AA) metabolism dysregulation plays a crucial role in the tumor initiation and progression of HCC, resulting in high reliance on AA availability. This makes HCC cells vulnerable to AA starvation, implying that restricting AA supply and utilization may offer a promising nutritional strategy in HCC therapy.</div><div>We delineate the pivotal physiological functions and aberrant alterations of various AA metabolisms in HCC. We systematically summarize the recent advances in agents, targets, antineoplastic effects, and mechanisms of various AA starvation strategies in HCC, including dietary restriction, circulating depletion, transporter blockade, and metabolic enzyme inhibition. We further discussed a suite of adaptive responses that enable HCC cells to survive with AA shortage. Targeting these adaptive pathways in combination with AA starvation may enhance the efficacy of HCC treatment.</div><div>This review aims to provide a comprehensive overview of progress in the field of AA starvation for HCC therapy and to explore novel therapeutic opportunities and strategies through nutritional intervention for HCC therapy.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189400"},"PeriodicalIF":9.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidimensional regulation of the microbe-TLR4 signaling Axis in colorectal cancer: From molecular mechanisms to microbe-targeted therapies 结直肠癌中微生物- tlr4信号轴的多维调控：从分子机制到微生物靶向治疗

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-22 DOI: 10.1016/j.bbcan.2025.189397

Caihou Zhang , Haimin Geng , Yurong Tan , Lili Wang

{"title":"Multidimensional regulation of the microbe-TLR4 signaling Axis in colorectal cancer: From molecular mechanisms to microbe-targeted therapies","authors":"Caihou Zhang , Haimin Geng , Yurong Tan , Lili Wang","doi":"10.1016/j.bbcan.2025.189397","DOIUrl":"10.1016/j.bbcan.2025.189397","url":null,"abstract":"<div><div>Colorectal cancer (CRC), the third most common cancer globally, arises from complex interactions between genetic predisposition, environmental factors, and gut microbiota dysbiosis. This review systematically analyzes the multidimensional regulatory mechanisms of the microbe-TLR4 signaling axis in CRC, including key pathways such as TLR4/NF-κB, MAPK, TRIF/IRF3, Keap1/NRF2/CYP2J2, and ceramide/β-catenin/SOAT1. These pathways drive tumor progression through metabolic reprogramming, immune modulation, and genotoxic effects. Therapeutic strategies targeting this axis encompass natural compounds (e.g., terpenoids, polysaccharides, saponins), traditional Chinese medicine formulas (e.g., Ganluyin, Xiao-Chai-Hu-Tang), microbiota therapies (probiotics, engineered bacteria, oncolytic viruses), and dietary and metabolic regulation (dietary fiber, methionine), exerting anti-tumor effects by inhibiting excessive TLR4 activation, repairing intestinal barriers, and regulating microbial balance. The review highlights challenges such as the complexity of signaling pathways, precise microbiota modulation, and drug delivery. At the same time, emerging technologies like single-cell multi-omics and artificial intelligence prediction models offer new directions for precision interventions. Targeting the microbe-TLR4 axis holds promise as an innovative strategy for CRC treatment.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189397"},"PeriodicalIF":9.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144704088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics 乳腺癌的代谢重编程：驱动进展的途径，耐药性和新兴治疗方法

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-21 DOI: 10.1016/j.bbcan.2025.189396

Pankaj Garg , Gargi Singhal , David Horne , Ravi Salgia , Sharad S. Singhal

{"title":"Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics","authors":"Pankaj Garg , Gargi Singhal , David Horne , Ravi Salgia , Sharad S. Singhal","doi":"10.1016/j.bbcan.2025.189396","DOIUrl":"10.1016/j.bbcan.2025.189396","url":null,"abstract":"<div><div>Breast cancer (BC), one of the most frequent causes of cancer-related death in women, is known to be a highly heterogeneous disease in regard to molecular subtypes, which seem to possess different metabolic profiles. Aberrant metabolism is well understood as one of the hallmarks of cancer and it contributes to BC progression, therapeutic resistance, and metastasis. Here, we analyze BC metabolism and how certain cancer types, such as hormone receptor-positive, HER2-positive, and triple-negative BC, use glycolysis, lipid metabolism, amino acid compulsion, and mitochondrial biogenesis to feed and proliferate. These metabolic hallmarks, in the context of the tumor microenvironments, are illustrated to highlight the metabolic byproducts that are derived from reprogrammed pathways and are vital to immunosuppression and tumor survival under low oxygen and nutrient availability. Furthermore, we emphasize novel trends in anticancer drugs designed to strike on these metabolic dependencies to suppress tumor growth. In addition to summing up current knowledge about metabolic reprogramming in BC, this review reveals new targets for specific treatments that might enhance prognosis in certain types of BC. This review aims to bridge basic scientific insights and clinical perspectives, guiding future metabolic interventions in BC toward clinically relevant, subtype-specific therapeutic strategies.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189396"},"PeriodicalIF":9.7,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144686926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From unearthing to an intriguing cancer-fighting target: the human BCL-2 promoter G-quadruplex and i-motif. 从发现到一个有趣的抗癌靶点：人类BCL-2启动子g -四重体和i-基序。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-20 DOI: 10.1016/j.bbcan.2025.189391

Pronamika Chetia, Amit Kumar

{"title":"From unearthing to an intriguing cancer-fighting target: the human BCL-2 promoter G-quadruplex and i-motif.","authors":"Pronamika Chetia, Amit Kumar","doi":"10.1016/j.bbcan.2025.189391","DOIUrl":"10.1016/j.bbcan.2025.189391","url":null,"abstract":"<div><div>Cancer is a global burden that calls for creative solutions. Among the several hallmarks of cancer, overexpression of the <em>BCL-2</em> oncogene serves as a factor for cancer cell proliferation and progression. Targeting the transcription machinery of the <em>BCL-2</em> oncogene is an effective approach against cancer since chemotherapy causes huge problems due to its catastrophic toxicity and accompanying side effects. Transcription of the <em>BCL-2</em> gene is primarily controlled by the P1 promoter and its upstream region, which is G-rich and can fold into G-quadruplexes (G4 or GQ), and i-motif structures. G4 and i-motif are secondary structures of nucleic acids that provide a platform for binding proteins, small molecules, peptide nucleic acids, etc. Such secondary structures can be targeted and have been extensively studied in the past few years. Therefore, it is reasonable to carry out an in-depth investigation of the G4 and i-motif structures in the <em>BCL-2</em> gene and its potential as a therapeutic target. Here, we will overview the discovery and structure of <em>BCL-2</em> G4 and i-motif structure and the proteins that bind to P1 promoter. Lastly, we will discuss <em>BCL-2</em> G4 and i-motif binding small molecules/ligands, and their anticancer activities and examine their potential for innovative cancer treatments.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189391"},"PeriodicalIF":9.7,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma 靶向YY1-Bcl2-c-Myc轴治疗非霍奇金淋巴瘤

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-19 DOI: 10.1016/j.bbcan.2025.189395

Mai P. Ho , Evagelia Skouradaki , Stavroula Baritaki , Etini Otumo , Benjamin Bonavida

{"title":"Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma","authors":"Mai P. Ho , Evagelia Skouradaki , Stavroula Baritaki , Etini Otumo , Benjamin Bonavida","doi":"10.1016/j.bbcan.2025.189395","DOIUrl":"10.1016/j.bbcan.2025.189395","url":null,"abstract":"<div><div>Non-Hodgkin lymphoma (NHL) presents a complex therapeutic challenge due to its heterogeneous nature and the high incidence of relapse following initial treatment. As such, patients who are more susceptible to treatment resistance face a poor prognosis with limited treatment options. With recent advances, the direct targeting of overexpressed gene products is a novel therapeutic approach to overcome resistance mechanisms in unresponsive NHL patients. In the pathogenesis of NHL, we suspect aberrant deregulations amongst three major oncogenes: Yin Yang 1 (YY1), B-cell lymphoma 2 (Bcl-2), and Myelocytomatosis oncogene (c-Myc). Through analyses of the reported literature data, we have determined, indeed, multiple cross-talk signaling pathways (i.e. with factors MDM2, NF-κΒ, SENP1, TGF-β, p53, ERK) for YY1, Bcl-2, and c-Myc that enable malignant cells to evade immune surveillance, promote tumor aggressiveness, and maintain resistance against various treatment modalities. In addition, we also present various approaches and agents to target each of the gene products, with discussion of challenges faced to generate such agents that specifically target the tumor cells.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189395"},"PeriodicalIF":9.7,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TXNIP in cancer: Unlocking biological insights and tackling clinical challenges TXNIP在癌症：解锁生物学见解和解决临床挑战。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-18 DOI: 10.1016/j.bbcan.2025.189394

Piercarlo Del Console , Luca Gelsomino , Cinzia Giordano , Ennio Pietramala , Daniela Bonofiglio , Sebastiano Andò , Stefania Catalano , Ines Barone

{"title":"TXNIP in cancer: Unlocking biological insights and tackling clinical challenges","authors":"Piercarlo Del Console , Luca Gelsomino , Cinzia Giordano , Ennio Pietramala , Daniela Bonofiglio , Sebastiano Andò , Stefania Catalano , Ines Barone","doi":"10.1016/j.bbcan.2025.189394","DOIUrl":"10.1016/j.bbcan.2025.189394","url":null,"abstract":"<div><div>Cancer remains a major global health challenge and one of the leading causes of mortality worldwide. Its development and progression involve complex genetic and molecular alterations, including the activation of oncogenes, as well as the inactivation of tumor suppressor genes (TSGs). These TSGs play critical roles in regulating cell cycle, genomic stability, and apoptotic pathways, with their dysfunction widely contributing to tumorigenesis and therapy response. Among the TSGs, Thioredoxin Interacting Protein (TXNIP) has gained attention as a key regulator with multifaceted roles in cancer biology. Mechanistic insights have identified TXNIP as a broad-acting protein involved in a variety of cellular responses, including oxidative stress, metabolism, immune regulation, and tumor suppression. This literature review critically examines the emerging clinical and experimental evidence of TXNIP’s functions in cancer, with a particular focus on breast cancer, the most frequently diagnosed malignancy in women. Furthermore, it explores promising therapeutic advances aimed at restoring TXNIP tumor-suppressive functions to slow cancer progression and improving patient outcomes.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189394"},"PeriodicalIF":9.7,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting hormone-related signals to reprogram the antitumor immune response in breast cancer: Research progress and application prospects 靶向激素相关信号重编程乳腺癌抗肿瘤免疫反应的研究进展及应用前景

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-18 DOI: 10.1016/j.bbcan.2025.189390

Shunchao Yan, Zhijie Zhang, Jiale Ji, Murshid Imam, Simiao Wang

{"title":"Targeting hormone-related signals to reprogram the antitumor immune response in breast cancer: Research progress and application prospects","authors":"Shunchao Yan, Zhijie Zhang, Jiale Ji, Murshid Imam, Simiao Wang","doi":"10.1016/j.bbcan.2025.189390","DOIUrl":"10.1016/j.bbcan.2025.189390","url":null,"abstract":"<div><div>Breast cancer is a heterogeneous disease with varying responses to hormonal therapies and immunotherapies. It is commonly characterized as a “cold” tumor; however, increasing evidence demonstrates the immunomodulatory effects of hormonal signals and an evolving tumor immune microenvironment following treatment. Several investigations have shown that anti-hormone treatment enhances the capacity of antitumor immune cells while reducing the population of immunosuppressive cells. Understanding the effects and mechanisms of hormone and anti-hormone therapies on the antitumor immune response is crucial for developing novel cancer treatment strategies. This review explores the complex interplay between hormonal signals and antitumor immune responses in breast cancer and outlines the research progress and potential applications of targeting hormone-related signals to reprogram the immune response against breast cancer. We also address the challenges, opportunities, and future directions in regulating hormonal signals to improve the efficacy of immunotherapy for individuals with breast cancer.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189390"},"PeriodicalIF":9.7,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers in cystic lesions of the pancreas: Controversies and advances 胰腺囊性病变的生物标志物：争议与进展。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-17 DOI: 10.1016/j.bbcan.2025.189392

Longyu Liu , Zhiyao Fan , Hanxiang Zhan

{"title":"Biomarkers in cystic lesions of the pancreas: Controversies and advances","authors":"Longyu Liu , Zhiyao Fan , Hanxiang Zhan","doi":"10.1016/j.bbcan.2025.189392","DOIUrl":"10.1016/j.bbcan.2025.189392","url":null,"abstract":"<div><div>Pancreatic cystic lesions (PCLs) represent a highly heterogeneous category of pancreatic abnormalities with an increasing prevalence due to advances in imaging modalities and an aging population. While the majority of PCLs are benign, a subset harbors a variable risk of malignant transformation. Current guidelines rely primarily on imaging features for risk stratification, but limitations in diagnostic accuracy have led to many unnecessary surgical procedures and conversely, missed opportunities for timely resection in cases that progress to malignancy.Recent advances in biomarker discovery hold great promise for improving the management of PCL. In this review, we focus on comparing the diagnostic efficacy of classical tumor markers, highlighting the controversies and challenges associated with each. In addition, we explore the heterogeneous expression of mucins in different subtypes of intraductal papillary mucinous neoplasms (IPMNs) and review the role of common genetic mutations and next-generation sequencing (NGS) in the genomic assessment of PCLs. Importantly, we summarize the results of several novel gene panels and evaluate their diagnostic performance and clinical potential. Although accurate diagnosis and risk stratification of PCLs remain challenging, advances in biomarkers and molecular techniques continue to reveal their potential in precision medicine, with promising implications for clinical translation.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189392"},"PeriodicalIF":9.7,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Yin yang 1: a potential regulator of immune related diseases and cancer immunity 阴阳1：免疫相关疾病和癌症免疫的潜在调节剂。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-07-17 DOI: 10.1016/j.bbcan.2025.189389

Yutong Tan , Dan Ye , Cheng Qian , Juanjuan Shan , Jiatao Li

{"title":"Yin yang 1: a potential regulator of immune related diseases and cancer immunity","authors":"Yutong Tan , Dan Ye , Cheng Qian , Juanjuan Shan , Jiatao Li","doi":"10.1016/j.bbcan.2025.189389","DOIUrl":"10.1016/j.bbcan.2025.189389","url":null,"abstract":"<div><div>Yin Yang (YY1) is a context-dependent bifunctional transcription factor, activating or repressing target gene transcription via transcriptional or post-translational way, participate in multiple physiological processes including development, cell proliferation, differentiation, DNA repair and cell apoptosis. Recent reports show that YY1 also functions as a key transcription factor in immune response. Immune system dysfunction is closely related to various disease such as autoimmunity and cancer progression, how YY1 modulates immune related disease progression has not been systematically discussed. In addition, although YY1 has been widely reviewed to be a tumor promoter or suppressor, the role of YY1 in cancer immune microenvironment modulation and immune escape is not completely clear. This review provides an overview about the role of YY1 in immune related disease progression, and focused on discussing how YY1 affects cancer immune escape. Then we talked about recent strategies explored for YY1-targeted therapy including both preclinical and clinical studies. Finally, the challenges and limitations via targeting YY1 in future research is also discussed.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 5","pages":"Article 189389"},"PeriodicalIF":9.7,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0